Table 3 Response to clinical scenarios
Scenario 1: Stage IV Diffuse Large B-cell Non-Hodgkin’s Lymphoma (n = 55) | ||
|---|---|---|
Treatment options for the older patient | Number | Percentage |
R-CHOP1 × 6 + Intrathecal Methotrexate | 26 | 47% |
R-CVP2 × 6 | 21 | 38% |
CHOP3 × 6 | 4 | 7% |
Palliative radiotherapy | 3 | 6% |
Best Supportive Care | 1 | 2% |
Treatment options for the younger patient | Number | Percentage |
RCHOP × 6 + Intrathecal Methotrexate | 45 | 82% |
R-CVP × 6 | 7 | 13% |
CHOP × 6 | 3 | 5% |
Palliative radiotherapy | 0 | 0% |
Best Supportive Care | 0 | 0% |
Factors affecting treatment decision | ||
Performance Status | 47 | 85% |
Cancer type | 37 | 67% |
Cancer stage | 20 | 36% |
Patient decision | 16 | 29% |
Co-morbidities | 15 | 27% |
Age | 14 | 25% |
Scenario 2: Stage IIB, Node positive, Hormone receptor positive Breast cancer (n = 53) | ||
Treatment options for the older patient | Number | Percentage |
Aromatase inhibitor × 5 years | 34 | 64% |
Tamoxifen × 5 years | 8 | 15% |
AC4 × 4 → T5 × 12, then endocrine treatment | 5 | 9% |
CMF6 × 6, then endocrine treatment | 1 | 2% |
FAC7 × 6, then endocrine treatment | 1 | 2% |
Others | 4 | 8% |
Treatment options for younger patient | Number | Percentage |
AC × 4 → T × 12, then endocrine treatment | 44 | 83% |
FAC × 6, then endocrine treatment | 5 | 9% |
CMF × 6, then endocrine treatment | 2 | 4% |
Others | 2 | 4% |
Aromatase inhibitor × 5 years | 0 | 0% |
Tamoxifen × 5 years | 0 | 0% |
Factors affecting treatment decision | Number | Percentage |
Cancer Stage | 38 | 72% |
Cancer Type | 32 | 60% |
Performance Status | 25 | 47% |
Age | 24 | 45% |
Patient decision | 16 | 30% |
Co-morbidities | 9 | 17% |